Merck reported strong Q1 growth with significant increases in key areas like oncology and vaccines, and raised full-year guidance despite some foreign exchange headwinds. Management maintained an optimistic tone, emphasizing a robust pipeline and successful product launches, which should reassure investors in the short term.

[1]